Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) shares fell 6.9% on Monday . The stock traded as low as $1.60 and last traded at $1.62. 565,685 shares changed hands during mid-day trading, a decline of 56% from the average session volume of 1,287,081 shares. The stock had previously closed at $1.74.

Separately, ValuEngine raised Titan Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, February 2nd.

The company has a quick ratio of 4.65, a current ratio of 5.24 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $22.83 million, a price-to-earnings ratio of -0.39 and a beta of 0.52.

Titan Pharmaceuticals (NASDAQ:TTNP) last issued its earnings results on Wednesday, November 14th. The specialty pharmaceutical company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.18. The business had revenue of $1.65 million for the quarter, compared to analyst estimates of $0.10 million. Titan Pharmaceuticals had a negative return on equity of 878.37% and a negative net margin of 168.73%. Analysts predict that Titan Pharmaceuticals, Inc. will post -1.98 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Perkins Capital Management Inc. acquired a new stake in Titan Pharmaceuticals in the 3rd quarter valued at $249,000. Virtu Financial LLC increased its holdings in Titan Pharmaceuticals by 530.0% in the 4th quarter. Virtu Financial LLC now owns 236,182 shares of the specialty pharmaceutical company’s stock valued at $53,000 after purchasing an additional 198,693 shares in the last quarter. Finally, Vanguard Group Inc increased its holdings in Titan Pharmaceuticals by 12.7% in the 3rd quarter. Vanguard Group Inc now owns 432,337 shares of the specialty pharmaceutical company’s stock valued at $90,000 after purchasing an additional 48,760 shares in the last quarter. 35.49% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Titan Pharmaceuticals (TTNP) Stock Price Down 6.9%” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/titan-pharmaceuticals-ttnp-stock-price-down-6-9/2813617.html.

About Titan Pharmaceuticals (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.

Read More: How does a reverse stock split work?

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.